Kyoto University has disclosed compounds and their nanoparticles acting as radiosensitizers for radiotherapy reported to be useful for the treatment of cancer.
Sookmyung Women’s University has described histone deacetylase 6 (HDAC6) inhibitors reported to be useful for the treatment of cancer, inflammation, autoimmune diseases and fibrosis.
Beigene Ltd. has divulged 4-(aminomethyl)-6-(1-methyl-1H-pyrazol-4-yl) isoquinolin-1 (2H)-one derivatives acting as protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.
Insilico Medicine IP Ltd. has identified heteroaromatic compounds acting as membrane-associated tyrosine- and threonine-specific Cdc2-inhibitory kinase (PKMYT1) inhibitors reported to be useful for the treatment of cancer.
Duality Biologics (Suzhou) Co. Ltd. has synthesized antibody-drug conjugates comprising anti-GPC3 antibodies covalently linked to exatecan derivatives through a linker. They are reported to be useful for the treatment of cancer.
Biotheryx Inc. has disclosed PROTAC compounds comprising an E3 ubiquitin-protein ligase binding moiety covalently linked to a SOS1 targeting moiety via linker.
Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have described fused heterocyclic compounds acting as receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors.
Molecular glues acting as zinc finger protein Helios (IKZF2) degradation inducers are described in a Gilead Sciences Inc. patent and reported to be useful for the treatment of cancer.
RSS